Norway's PCI Biotech sees promising data ahead of key study -CEO
April 24, 2018 at 00:11 AM EDT
OSLO, April 24 (Reuters) - Norwegian drug maker PCI Biotech has seen promising results from its bile duct cancer study ahead of a key second phase, but will need extra capital or a partnership to finalise a treatment, its chief executive told Reuters.